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Activation of kinases signalling pathways contributes to various malignant phenotypes in human cancers, including breast tumour. To
examine the possible activation of these signalling molecules, we examined the phosphorylation status in 12 protein kinases and
transcription factors in normal primary human mammary epithelial cells, telomerase-immortalised human breast epithelial cell line, and
two breast cancer lines, MDA-MB-468 and MCF-7, using Kinexus phosphorylated protein screening assays. The phosphorylation of
FAK, mTOR, p70S6K, and PDK-1 were elevated in both breast cancer cell lines, whereas the phosphorylation of AKT, EGFR, ErbB2/
Her2, PDGFR, Shc, and Stat3 were elevated in only one breast cancer line compared to normal primary mammary epithelial cells and
telomerase-immortalised breast epithelial cells. The same findings were confirmed by Western blotting and by kinase assays. We
further substantiated the phosphorylation status of these molecules in tissue microarray slides containing 89 invasive breast cancer
tissues as well as six normal mammary tissues with immunohistochemistry staining using phospho-specific antibodies. Consistent
findings were obtained as greater than 70% of invasive breast carcinomas expressed moderate to high levels of phosphorylated PDK-
1, AKT, p70S6K, and EGFR. In sharp contrast, phosphorylation of the same proteins was nearly undetectable or was at low levels in
normal mammary tissues under the same assay. Elevated phosphorylation of PDK-1, AKT, mTOR, p70S6K, S6, EGFR, and Stat3 were
highly associated with invasive breast tumours (Po0.05). Taken together, our results suggest that activation of these kinase pathways
by phosphorylation may in part account for molecular pathogenesis of human breast carcinoma. Particularly, moderate to high level
of PDK-1 phosphorylation was found in 86% of high-grade metastasised breast tumours. This is the first report demonstrating
phosphorylation of PDK-1 is frequently elevated in breast cancer with concomitantly increased phosphorylation of downstream
kinases, including AKT, mTOR, p70S6K, S6, and Stat3. This finding thus suggested PDK-1 may promote oncogenesis in part through
the activation of AKT and p70S6K and rationalised that PDK-1 as well as downstream components of PDK-1 signalling pathway may
be promising therapeutic targets to treat breast cancer.
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Breast cancer remains to be a major cause of death in women
worldwide, despite improvements in cancer prevention, early
detection, treatment, and understanding the molecular patho-
genesis. It hence demands an urgent need to unveil the exact
mechanism of oncogenesis and tumour progression, which may
prelude the development of new strategies for treatment. Breast
carcinoma emerges through multistep processes progressing from
hyperplasia to premalignant change, in situ carcinoma, invasion,
and distal metastasis, in concomitant with gain of oncogenic
activities and loss of tumour suppressor gene functions.
Protein kinases have been implicated in playing crucial roles in
regulating cell growth, metabolic responses, cell proliferation,
migration, and apoptosis, which altogether attribute tumori-
genesis. Constitutive activation of these protein kinases, mainly
by phosphorylation, was implicated in contributing to malignant
phenotypes in a number of human cancers including breast
carcinoma (Pandolfi, 2004; Saal et al, 2005; Zhang et al, 2005).
These protein kinases are normally phosphorylated by either
upstream protein kinases or by autophosphorylation in response
to cell signals.
Among growth factors, insulin was well studied in the past few
decades. Binding of insulin to receptors initiates phosphoinositol
3-OH-kinase (PI3-K) mediated phosphorylation and hence
generates phosphatidyl-inositol 3,4-biphosphate and phos-
phatidyl-inositol 3,4,5-triphosphate. These lipid products serve as
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smembrane docking sites for recruiting pleckstrin homology (PH)-
containing proteins. Among them, 3-phosphoinositide-dependent
protein kinase-1 (PDK-1) was identified to be an immediate
downstream mediator of PI3-K and was activated upon phosphory-
lation on residue Ser-241 (Casamayor et al, 1999). Activated PDK-1
controls cell proliferation, survival, nutrients uptake and storage, by
further activating its downstream AGC (cAMP-dependent, cGMP-
dependent, protein kinase C) family of protein kinases including AKT
(Alessi et al, 1997; Wick et al, 2000b), protein-kinase C (PKC) (Le
Good et al, 1998; Balendran et al, 2000), serum- and glucocorticoid-
induced kinase (SGK) (Mora et al, 2004), and ribosomal p70S6 kinase
(Pullen et al, 1998). Hence, PDK-1 functions as a pivotal signalling
molecule at the apex of complex networks of intracellular signalling
(Toker and Newton, 2000; Storz and Toker, 2002).
Among downstream kinases, AKT is one of the most extensively
studied PDK-1 substrates. Its activation has been implicated in
a number of human cancers by promoting proliferation and
inhibiting apoptosis caused by various death stimuli (Del Peso
et al, 1997; Franke et al, 1997; Kulik et al, 1997). AKT is activated
in response to survival signals from growth factors or cytokines via
mechanisms involving PI3-K and PDK-1 (Alessi et al, 1997; Franke
et al, 1997; Kulik et al, 1997; Bellacosa et al, 1998). Upregulation
of AKT by mutation of PTEN (a tumour suppressor gene that
antagonises AKT pathway) or amplification PIK3CA (encodes
catalytic subunit of PI3-K) were reported in a number of human
cancers including breast carcinoma (Vivanco and Sawyers, 2002;
Lee et al, 2005; Levine et al, 2005). Regarding other receptor
tyrosine kinases, breast cancer cells also produce platelet-derived
growth factor (PDGF) and its receptors, through autocrine or
paracrine mechanisms, to modulate growth, survival, and differ-
entiation of breast tissues (Shao et al, 2000).
Another downstream target of AKT is the mammalian target of
rapamycin (mTOR) (Scott et al, 1998; Nave et al, 1999; Sekulic
et al, 2000). It is a serine/threonine kinase, which phosphorylates
at least three downstream substrates: the translation repressor
eIF4E-binding protein (4E-BP) (von Manteuffel et al, 1997; Gingras
et al, 1999; Nojima et al, 2003); p70S6K, which phosphorylates
ribosome protein S6 (Nojima et al, 2003); and signal transducer
and activator of transcription 3 (Stat3) (Yokogami et al, 2000;
Kusaba et al, 2004). Normally, activation of Stat3 takes place upon
cytokine or growth factor stimulation. First, Stat3 was recruited to
cytoplasm followed by phosphorylatation on Y705 by receptor-
associated kinases. Then activated Stat3 leads to dimer formation,
nuclear localisation, and regulation of gene expression (Darnell
et al, 1994; Zhong et al, 1994). Additional phosphorylation on S727
by upstream kinases may augment its transcriptional activation
on target genes (Lim and Cao, 2001; Fu et al, 2004). mTOR is one
of the key kinases that appears to mediate phosphorylation of
Stat3 on S727 (Yokogami et al, 2000; Yonezawa et al, 2004). Taken
together, these upstream signalling molecules including PI3-K,
PDK-1, AKT and mTOR comprise regulatory pathways controlling
cell growth, metabolism, proliferation, differentiation, motility,
and survival, which attribute the overall malignancy phenotypes in
human cancers (Castedo et al, 2002; Carraway and Hidalgo, 2004;
Chan, 2004; Xu et al, 2004; Zhou et al, 2004).
Additional signalling mediators were also implicated in the
pathogenesis of breast cancers. c-Jun, a major component of the
AP-1 transcription factor, was reported to be either proapoptotic
(Cuadrado et al, 2004; Qi et al, 2004) or antiapoptotic (Johnsto
et al, 1999; Huang et al, 2004) depending upon cellular contexts.
One example of cellular regulators involved in the phosphorylation
of c-Jun in breast cancer was demonstrated to be the mitogen-
activated protein kinase phosphatases (Wang et al, 2003). On the
other hand, hepatocyte growth factor receptor, c-Met (Edakuni
et al, 2001; Parr and Jiang, 2001; Elliott et al, 2002; Lengyel et al,
2005), and the focal adhesion kinase (FAK) regulate multiple
cellular processes including growth, differentiation, adhesion,
motility and apoptosis. Furthermore, high expression of FAK in
breast cancer is related to activation of AKT (Schmitz et al, 2005)
and to the overexpression of receptor molecules such as ErbB2/
Her2 and EGFR (Lemmon, 2003). Lastly, the roles of amplified Shc
signalling, substrates for most receptor tyrosine kinases, in breast
tumourgenesis and metastasis were studied recently (Mauro et al,
1999; Dankort et al, 2001; Finlayson et al, 2003).
Although increased phosphorylation of AKT and mTOR in breast
cancer have been recently reported (Noh et al, 2004; Zhou et al,
2004; Zhang et al, 2005), limited number of studies has contrasted
the phosphorylation profiles of large panel of protein kinases
among normal and invasive breast cancer tissues. Further, although
PDK-1 is one of the crucial downstream targets of PI3-K signalling
and a key upstream kinase of AKT, it remains unclear whether
PDK-1 is activated in primary breast cancer tissues. Thus, we
examined the phosphorylation status of 10 protein kinases as well
as two transcription factors (c-Jun and Stat3) in normal primary
human mammary epithelial cells (HMEC), telomerase-immortalised
human breast cells (TERT), and breast cancer cell lines (MDA-MB-
468 and MCF-7) using Kinexus phosphorylated protein screening
assays. In addition, consistent results were obtained by using
Western blottings and AKT kinase assay in which the phosphoryla-
tion levels of PDK-1 were significantly elevated in both human
breast cancer cell lines, but at basal level in normal primary HMEC.
Further, we examined whether phosphorylation of PDK-1,
mTOR, and p70S6K was similarly elevated in breast primary
tumours using tissue microarray slides (TMAs). Interestingly,
consistent finding was obtained as increased phosphorylation of
these protein kinases was detected in breast cancerous tissues. In
sharp contrast, phosphorylation of the same molecules was at
negligible levels in normal breast tissues. In addition, the enhanced
phosphorylation in kinases was positively associated with disease
progression from normal breast epithelial to invasive breast
carcinoma (Po0.05). Finally, we demonstrated that elevated
phosphorylation of PDK-1 was frequently found in high-grade
metastasised breast tumours and was significantly associated with
increased phosphorylation of its downstream kinases (Po0.05),
indicating phosphorylation of PDK-1 may activate signalling
cascades, which altogether contribute to breast cancer.
MATERIALS AND METHODS
Breast cell lines and culture
Normal primary HMEC were purchased from Cambrex Inc. (East
Rutherford, NJ, USA) and were maintained in mammary epithelial
growth medium as recommended by the manufacturer. Telome-
rase immortalised breast epithelial (TERT) and the spontaneous
immortalised mammary epithelial cells MCF10A, gifts from Dr
Stephen Ethier at the Karmanos Cancer Institute, Wayne State
University (Detroit, Michigan), were cultured in F-12 medium
containing 5% FBS, 5mgml
 1 insulin, 1mgml
 1 hydrocortisone,
10ngml
 1 EGF (Sigma, St Louis, MO, USA), 100Uml
 1 penicillin
and 100mgml
 1 streptomycin (Invitrogen Life Technologies,
Carlsbad, CA, USA). Human breast cancer cell lines, MCF-7 and
MDA-MB-468, were purchased from American Type Culture
Collection (Manassas, VA, USA) and were maintained in 90%
Dulbecco’s modified Eagle’s medium supplemented with 10%
foetal bovine serum (FBS) and antibiotics (100Uml
 1 penicillin,
100mgml
 1 streptomycin) (Invitrogen Life Technologies, Carlsbad,
CA, USA) at 371Ci n5 %C O 2.
Examination of the phosphorylation profiles on kinases
derived from normal breast and breast cancer lines
Cultured cells at subconfluent healthy state were collected in
ice-cold PBS containing 1mM PMSF, 2mM sodium orthovanadate
(Sigma Co., St Louis, MO, USA), 2mM NaF, and complete protease
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sinhibitor cocktail (Boehringer Mannheim, Germany) and then
were lysed in modified radioimmunoprecipitation (RIPA) buffer
containing the above protease and phosphatease inhibitors.
Quantitation of total protein concentrations in the cell lysates
was determined by Bio-Rad Bradford assay. In total, 100mg of total
proteins derived from HMEC, TERT, MCF-7, or MDA-MB-468
were subjected to protein phosphorylation analysis on 12 cell
signalling molecules using Kinexus KCPS-1.0 phosphoprotein
profiling screen software (Kinexus Bioinformatics Corporation in
Vancouver, British Columbia, Canada). This analysis combines
proprietary methodologies with the analytical techniques involving
gel electrophoresis, immunoblotting, and protein visualisation via
enhanced chemiluminescence (ECL). Briefly, the KCPS-1.0 screen
detects the target proteins in two steps. First, molecules were
separated by gel electrophoresis based on their molecular weights,
and then were detected by their immunoreactivity with highly
validated phospho-specific antibodies. The panel of antibodies
used in this study harbour specific reactivities with phosphory-
lated AKT (S473), c-Jun (S73), c-Met (Y1230/Y1234/Y1235), EGFR
(Y1068), ErbB2/Her2 (Y1248), FAK (Y576), mTOR (S2448),
p70S6K (T389), PDGFR (Y716), PDK-1 (S241), Shc (Y239/Y240),
and Stat3 (S727). The resulting immune complexes were subjected
to a multiplexing apparatus, and the quantitation of the bands is
visualised using ECL followed by a highly sensitive imaging system
with a 16-bit camera and a quantitation software to analyse the
chemiluminescent samples. Each sample’s immunoblot was
scanned at its maximum time to ensure that the signal from the
strongest immunoreactive protein on the immunoblot remains
below saturation. It thus provides accurate quantitation over a
2000-fold range of linearity.
TMA slides and immunohistochemistry (IHC) staining
Multiple sets of breast TMA slides were purchased from BioChain
Institute, Inc. (Hayward, CA, USA), which altogether gave rise to
six normal breast epithelium and 89 of invasive breast carcinoma.
Among them, 83 of breast tumours were categorised into four
stages as described (Elston and Ellis, 1991) and were recommended
by the American Cancer Society, whereas the remaining six breast
tumours were uncertain regarding disease stages. IHC staining was
performed utilizing immunoperoxidase techniques described by
the manufacturer. Reactions were carried out in TBS buffer (20mM
Tris plus 140mM NaCl, pH 7.6) supplemented with 0.1% Tween-20
unless specified. Briefly, slides that contain paraffin sections were
deparaffinised in xylene, rinsed through two changes of 100%
ethanol, rehydrated in graded ethanol (95–70%) and water, and
were further subjected to heat-induced epitope retrieval in either
1m M ethylenediaminetetraacetic acid (EDTA, pH 8.0, for phos-
phorylated EGFR and Stat3) or 10mM citrate buffer (pH 6.0, for the
remaining kinases in this study). Endogenous peroxidase activity
was blocked with 3% hydrogen peroxide and nonspecific binding
was prevented by incubation with 3% normal serum for 1h at
room temperature. Slides were then incubated with adequately
diluted phosphor-specific primary antibodies (in TBS containing
3% normal serum) at 41C for an overnight. After washing with
TBS buffer, the primary immune complexes were reacted with
biotinylated secondary antibodies provided in ABC kits (Vector
Laboratories, Inc., Burlingame, CA, USA) and the resulting
complexes were detected upon the addition of a chromogen, 3-
amino-9-ethylcarbazole (AEC, DakoCytomation, Inc., Carpinteria,
CA, USA). After counterstaining of nuclei with haematoxylin
(Fisher Scientific, Middletown, VA, USA), slides were sealed in
Crystal/Mount aqueous-based mounting Medium (Biomedia Inc.,
Texarkana, Arkansas).
The primary antibodies used in this study were purchased from
Cell Signaling Technology Inc. (Beverly, MA) and were highly
validated by the manufacturer. The following antibodies were
applied in IHC staining: antitotal PDK-1 (recognises all forms
PDK-1 regardless phosphorylation status,1:50 dilution, catalog #
3062) and phosphor-specific antibodies including PDK-1 (S241,
1:50 dilution, catalog # 3061); AKT (T308 and S473, 1:25 dilution,
catalog # 4056 and 9277 respectively); mTOR (S2448, 1:50 dilution,
catalog # 2971); p70S6K (T389, 1:300 dilution, catalog # 9206);
S6 ribosomal protein (S235/236, 1:50 dilution, catalog # 2211);
Stat3 (S727 and Y705, 1:50 dilution, catalog # 9134 and 9135,
respectively); and EGFR (Y1068, 1:50 dilution, catalog # 2234).
The overall intensity of IHC staining on ductal and lobular
regions within each tissue was scored by eyes with the aids of an
inverted microscope and was graded as following: 0, negative
staining; 1, weak staining; 2, moderate staining; and 3, intensive
staining. Scores were independently graded by two researchers
(HL and JL). In order for a tissue to be grouped as positive for
phosphorylation, the score had to be 2 or greater.
Statistic analysis
Statistic analysis was carried out using SPSS software version 13.0
(SPSS Inc., Chicago, IL, USA).
Student’s t-test was to analyse if phosphorylated kinases
correlate with invasive breast carcinomas whereas the Bivariate
Pearson w
2 tests to relate the phosphorylation of PDK-1 to other
kinases that were studied in this report. Correlation was
considered to be significant if the correlation coefficient P is less
than 0.05. All P-values were two-sided.
Western blot analysis
For Western blot analysis, 100mg of proteins derived from total cell
lysates were resolved on SDS–PAGE and transferred onto PVDF
membrane. The same phospho-specific antibodies that were used
in IHC were used to detect the corresponding phosphorylated
proteins on the membrane. Monoclonal antibody to glyceralde-
hydes-3-phosphate dehydrogenase (GAPDH; Biochemistry Lab,
Temecula, CA, USA) was used to verify uniform protein loading.
All blots were scanned with the Image Quant software using an
electrochemifluorescence (ECF) Western blotting detection system
(Amersham Corp., Arlington Heights, IL, USA) on a Molecular
Dynamics Storm PhosphorImager (Sunnyvale, CA, USA).
AKT kinase assay
In total, 500mg of proteins derived from total cell lysates was
immunoprecipitated with immobilised anti-AKT monoclonal
antibody (1G1, Cell Signaling Technology, Beverly, MA, USA),
and the subsequent AKT kinase assay was performed with GSK-3a/b
as substrates using a commercial kit (Cell Signaling Technology,
Beverly, MA, USA). Phospho-specific antibody to GSK-3a/b
(Ser21/Ser9) was used for phosphorylated protein detection.
RESULTS
Comparison of protein phosphorylation between normal
breast epithelial cells and breast cancer cell lines
Kinase or transcription factor activation by phosphorylation has
been implicated to play pivotal roles in human cancers including
breast carcinoma. We first compared the phosphorylation profiles
of 10 protein kinases and two transcription factors (Stat3 and c-
Jun) between normal primary HMEC, TERT, and two breast cancer
cell lines, noninvasive MCF-7 and invasive MDA-MB-468 (Krueger
et al, 2001). We found that phosphorylation of mTOR(S2448) was
elevated in about two-fold in both breast cancer cell lines
compared to HMEC and TERT. Phosphorylation of PDK-1(S241)
was two-fold higher in TERT and was five- to six-fold elevated in
both breast cancer cell lines compared to HMEC (Table 1). Further,
phosphorylation of p70S6K(T389) was elevated 10- to 35-fold in
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sboth breast cancer cell lines while nearly basal level was retained
in HMEC and in TERT (Table 1). Phosphorylation of FAK(Y576)
was also four-fold elevated in MDA-MB-468 cells and only
1.6-fold elevated in MCF-7 cells (Table 1). On the other hand,
the phosphorylation of AKT(S473), EGFR(Y1068), ErbB2/
Her2(Y1248), PDGFR(Y716), Shc(Y239), and Stat3(S727) were
elevated only in MDA-MB-468 breast cancer cells, but retained
basal level in MCF-7 cells compared to HMEC and TERT (Table 1).
Phosphorylation of c-Met, however, was nearly unaffected in both
breast cancer cell lines (Table 1). In contrast, the phosphorylation
of c-Jun was reduced in both breast cancer cell lines and TERT,
compared to HMEC (Table 1).
Elevated phosphorylation of PDK-1(S241) in breast cancer
as evidenced by IHC staining on primary tissues fixed on
TMA slides and by Western blotting
To further confirm our investigation on increased phosphoryla-
tion in breast cancers, we have applied IHC staining on breast
tumours fixed on TMA slides to examine the phosphorylation
status of PDK-1, AKT, mTOR, p70S6K, S6, Stat3, and EGFR.
Activation of PDK-1 pathway can be mediated by upstream insulin
or by other receptor tyrosine kinases and was reported to be
critical in regulating survival, metabolism, and cell cycle control
(Osaki et al, 2004). The roles of PDK-1 in human cancers were
implicated by the finding that overexpression of PDK-1 trans-
formed mammary epithelial cells (Xie et al, 2003). However,
whether the phosphorylation of PDK-1 was elevated in primary
breast tumours has not been assessed yet. We therefore examined
phosphorylation of PDK-1 at residue S241 in a total of six normal
breast tissues and 89 invasive breast carcinomas using IHC
staining on TMA slides. Breast cancer tissues, which revealed
moderate to high level of PDK-1 phosphorylation (scores 2 and 3),
were grouped as positives and were observed in 72 out of 89
(80.9%) invasive breast tumours (Table 2). In contrast, nearly all
of normal breast tissues showed only basal or low level of staining
(scored 0 and 1) under the same staining condition (Table 2).
Interestingly, increased PDK-1 phosphorylayion was significantly
correlated with invasive breast carcinoma (Po 0.05) as illustrated
by the Student’s t-test using SPSS software (Table 2). Importantly,
similar results were obtained using Western blottings demonstra-
ting that PDK-1 phosphorylayion levels were remarkably elevated
in MCF-7 and MDA-MB-468 breast cancer cell lines compared to
HMEC and MCF-10A cells (Figure 3A). Taken together, our data
thus suggest PDK-1 might play an important role in pathogenesis
of breast carcinomas. Moreover, phosphorylated PDK-1 was
predominately cytoplasmic localised (Figure 1), which was in
close agreement with other finding suggested that retention of
PDK-1 in cytoplasm provides close proximity in signalling its
downstream targets in breast carcinomas (Lim et al, 2003).
Furthermore, the expression of total PDK-1 (both phosphorylated
and unphosphorylated) negligibly differed among all TMA tissues,
indicating the differences in the degree and frequency of
phosphorylation was more likely resulted from differential
phosphorylation levels rather than quantitative variations (top
row of Figure 1).
Phosphorylation of AKT in breast carcinoma
The oncogenic effects of AKT in human cancers depended on its
ability of inducing multiple downstream cascades to promote cell
survival, tumour growth and progression (Bellacosa et al, 1998;
Franke et al, 2003; Osaki et al, 2004). Deregulation of this pathway
leads to upregulation of AKT signalling cascades was commonly
found in variety of human cancers including breast carcinoma
(Vivanco and Sawyers, 2002; Lee et al, 2005; Levine et al, 2005). It
was evidenced that AKT signalling was transduced from upstream
PI3-K (Franke et al, 1995). However, the molecular linkage
between PI3-K and AKT in the primary breast tumours remained
to be illustrated. Although in vitro model demonstrated that PDK-
1 is the AKT (T308) kinase (Alessi et al, 1997; Wick et al, 2000b;
Williams et al, 2000), the clinical association between these two
molecules remained to be validated. In this study, we have
demonstrated significant correlation in these two kinases regard-
ing their phosphorylation profiles in primary breast tumours.
Similar to the increased phosphorylation frequency observed in
PDK-1(S241), moderate to high levels of AKT(T308) phosphoryla-
tion was observed in 72 out of 89 (80.9%) of invasive breast
tumours (Table 2, Figure 2). In addition, the cellular localisation of
AKT(T308) closely resembled that of PDK-1, altogether suggested
both molecules were correlated in vivo and they may involve in the
same signalling cascade in primary breast tumour.
Table 1 Protein phosphorylation profiles in TERT and in breast cancer
lines relative to that in normal primary HMEC
a
Protein TERT MCF-7 MDA-MB-468
AKT (S473) 0.43 0.96 2.87
C-Jun (S73) 0.15 0.45 0.02
C-MetR (Y1230) 1.37 0.50 1.37
EGFR (Y1068) 0.51 0.21 5.22
ErbB2/Her2 (Y1248) 0.38 0.27 4.51
FAK (Y576) 0.72 1.59 4.14
mTOR (S2448) 0.71 2.00 2.17
P70S6K (T389) 0.79 35.26 10.22
PDGFR (Y716) 0.52 0.05 8.89
PDK-1 (S241) 2.03 6.45 5.07
Shc (Y239) 1.82 0.20 3.04
Stat3 (S727) 0.26 0.77 2.71
aPhosphorylation of 10 kinases and two transcription factors (c-Jun and Stat3) in
TERT and in breast cancer cell lines (MCF-7 and MDA-MBB-468) relative to that in
normal primary HEMC, which was set as value 1.0. Data were derived from the
protein phosphorylation analysis using Kinexus KCPS-1.0 phosphoprotein profiling
screen software as described in the Materials and methods.
Table 2 Elevated protein phosphorylation correlated with invasion of
breast cancer and with phosphorylation of PDK-1
Number of
positives
Normal Cancer P-value
Protein
phosphorylation
a N¼6
a 89
a Invasion
b
PDK-1
phosphorylation
c
PDK-1 (S241) 0 (0%) 72 (80.9%) o0.05
AKT (T308) 0 (0%) 72 (80.9%) o0.05 o0.05
AKT (S473) 0 (0%) 31 (34.8%) o0.05 o0.05
mTOR (S2448) 0 (0%) 40 (44.9%) o0.05 o0.05
P70S6K (T389) 0 (0%) 64 (71.9%) o0.05 o0.05
S6 (S235/236) 0 (0%) 52 (58.5%) o0.05 o0.05
Stat3 (S727) 0 (0%) 40 (44.9%) o0.05 o0.05
Stat3 (Y705) 0 (0%) 23 (25.8%) o0.05 40.05
EGFR (Y1068) 0 (0%) 67 (75.3%) o0.05 o0.05
aThe total numbers of breast tissues on TMA slides that experienced positive
outcomes (scores 2 and 3) following IHC staining using various phospho-specific
antibodies (as described in the Materials and methods) were counted. The resulting
numbers were divided by either 6 (total number of normal breast tissue) or 89 (total
number of invasive breast carcinoma) to obtain percentage values shown in the
parenthesis.
bStudent’s t-test was to analyse whether phosphorylated kinases
correlated with invasive breast carcinomas.
cBivariate Pearson w
2 test was to correlate
the phosphorylation of PDK-1 to the remaining kinases. Both statistic analyses were
carried out using SPSS software version 13.0 (SPSS Inc., Chicago, IL, USA). Significant
correlation is rendered if the correlation coefficient P is less than 0.05.
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sIn addition to T308, S473 is another phosphorylation residue on
AKT that was targeted by different kinase(s) (Hresko et al, 2003;
Feng et al, 2004; Partovian and Simons, 2004; Sarbassov et al,
2005). In this study, however, the frequency of AKT(S473)
phosphorylation in breast cancer was lower (34.8%) than those
of AKT (T308) and PDK-1(S241) (Tables 2 and 3, Figure 2).
PDK-1 AKT AKT mTOR
(S241) (S473) (S2448) 
p70S6K
(T389)
(T308)
S6 EGFR STAT3 
 (S235/S236)  (S727) (Y1068)
Figure 2 Gross view of IHC staining on TMA slides fixed with normal breast tissues and invasive breast tumours. Representative examples of IHC stained
TMA slides to detect phosphorylated molecules as described in the legend to Figure 1. Nuclear staining with haematoxylin was omitted and hence red
outcome indicates phosphorylated proteins in breast tissues. Noticeably, the normal breast tissues, arrayed in the left-hand row and labeled with a black
arrow, revealed poor phosphorylation and remained colourless upon IHC staining. The most bottom spot (black square) of the normal tissue row was
derived from placenta, which served as examples of positive staining for phosphorylation of PDK-1 (S241) and AKT (T308). The spot right above the
placenta tissue was a paraffin control, which contained no tissue, whereas the remaining spots contained normal breast tissue in duplicates.
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Figure 1 Elevated phosphorylation of PDK-1/AKT pathway in invasive breast cancer. Normal (left panel) and cancerous (right panel) breast tissues fixed
on TMA slides were subjected to IHC staining using highly validated phosphor-specific antibodies to examine the phosphorylation status of target proteins.
As a control, a primary antibody recognises all forms of PDK-1 were similarly used in IHC staining and the representive example tissues were shown on the
top row. The resulting positive immune complexes gave rise to red end product at target antigen sites following the addition of the chromogene, AEC,
whereas the unphosphorylated proteins remained colourless. After nuclear staining with haematoxylin (blue dye), representative normal breast tissues (left
column) as well as positive examples of breast tumours (right column) were photographed.
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phosphorylation on AKT (S473) (scores 2 or greater) also revealed
increased phosphorylation on AKT(T308) (data not shown),
indicating AKT(S473) very likely prelude by phosphorylation of
AKT(T308). Moreover, AKT(S473) localised in both cytoplasmic
and cell membrane whereas phosphorylated AKT (T308) was
predominant in the cytoplasm (Figure 1). Nevertheless, phosphory-
lation of AKT on both residues, T308 and S473, was significantly
associated with invasive breast tumours (Po0.05) as shown in
Table 2.
To validate our observations further, two independent studies
were carried out to reveal the phosphorylation status and kinase
activation of AKT in breast cancer cell lines. As shown in
Figure 3A, AKT phosphorylation at T308 was significantly higher
(and nearly equally) in both cancer lines than in HMEC and
in non-cancerous MCF10A cells. However, phosphorylation at
AKT(S473) was variable between two cancer lines. As shown in
Figure 3A, MDA-MB-468 harboured remarkable elevation whereas
MCF-7 contained modest increase (Figure 3A). In addition, MDA-
MB-468 also retained far more AKT kinase activity than MCF-7,
although they both had higher AKT kinase activity than HMEC
(Figure 3B). The profile of AKT kinase activities in normal and
cancer cells resembled more close to S473 than T308 (Figure 3A
and B), which is again similar to the finding from Kinexus kinase
assay on S473 (Table 1). Taken together, our data suggest that
activation of AKT pathway is consistently higher in breast cancer
lines than in noncancerous breast epithelia, and hence suggest that
AKT activation may play critical roles in the tumorigenesis of
human mammary cancer.
Elevated phosphorylation of mTOR/p70S6K/S6 pathway in
breast cancer
AKT promotes oncogenesis through phosphorylation of several
downstream targets. Among them, mTOR(S2448) was phosphory-
lated directly by AKT following growth factor stimulation
(Reynolds et al, 2002). Phosphorylation of mTOR(S2448) has been
suggested to be an important hallmark for such activated pathway,
which subsequently signals downstream targets including p70S6K
and S6 (Martin and Blenis, 2002; Yonezawa et al, 2004). We have
found 40 (44.9%) breast cancer tissues revealed moderate to high
levels of mTOR(S2448) phosphorylation, whereas 64 (71.9%) and
52 (58.5%) out of 89 invasive breast carcinoma gave rise to positive
staining (scores 2 and 3) on phosphorylated p70S6K(T389) and
S6(S235/236), respectively (Table 2). Nevertheless, phosphoryla-
tion of all three molecules were positively correlated with invasive
breast carcinoma (Po0.05) (Table 2) in this study. Interestingly,
the cellular localisations among these three kinases were strikingly
different. Phosphorylated mTOR and S6 resided predominately in
the cytoplasm whereas phosphorylated p70S6K were predomi-
nately in the nuclei, suggesting trafficking mechanisms were
involved to transduce signals between cytoplasm and nucleus
compartments.
Moreover, the phosphorylation status of mTOR(S2448) was
further examined in breast cancer lines and in HMEC using
Western blotting. As demonstrated in Figure 3A, dramatic elevated
phosphorylation of mTOR(S2448) was consistently observed in
both breast cancer lines, but was nearly undetectable in primary
HMEC or in MCF10A. It thus implicates that maintaining mTOR in
highly phosphorylated and activated state may attribute breast
cancer.
Phosphorylation of Stat3 in breast cancer
Numerous studies suggested constitutively activated Stat3 plays an
oncogenic role in many types in human cancers including breast
cancer (Bowman et al, 2000; Garcia et al, 2001). Activation of Stat3
requires phosphorylation on two residues S727 and Y705 (Wen
et al, 1995; Jain et al, 1999; Lim and Cao, 2001). mTOR is one of the
Table 3 Frequency of elevated protein phosphorylation at various stages
of breast cancer
Number of positives
Stages
I II III IV
Phosphorylated
protein
a N¼35 2 7 2 1
PDK-1 (S241) 1 (33%) 42 (80%) 6 (86%) 18 (86%)
AKT (T308) 1 (33%) 43 (83%) 6 (86%) 18 (86%)
AKT (S473) 1 (33%) 20 (39%) 1 (14%) 6 (29%)
mTOR (S2448) 1 (33%) 25 (48%) 2 (29%) 8 (38%)
P70S6K (T389) 1 (33%) 36 (69%) 7 (100%) 16 (76%)
S6 (S235/236) 2 (66%) 29 (56%) 4 (57%) 14 (67%)
Stat3 ( S727) 1 (33%) 27 (52%) 1 (14%) 7 (33%)
EGFR (Y1068) 2 (66%) 42 (81%) 3 (43%) 14 (67%)
aNumber of breast tumours in each stage that contained positive protein
phosphorylation (scores 2 and 3 upon IHC staining on TMA slides) was counted
and was divided to the total number (N) of breast tumours in each group, which gave
rise to the frequency (%) of tumours that retained elevated protein phosphorylation.
The tumours were classified according to the TNM systems (Elston and Ellis, 1991)
(T: invasion of primary tumour; N: metastasis to regional lymph nodes; M: metastasis
to distal organs) as well as the guidelines from American Cancer Society.
MDA-MB-468
AKT(T308)
Stat3(S727)
GAPDH
mTOR(S2448)
EGFR(Y1068)
AKT(S473)
PDK(S241)
MCF-7
MCF10A
HMEC
MCF-7
MDA-MB-468
HMEC
P-GSK-3  / 
(S21/9)
A
B
Figure 3 Elevated protein phosphorylation and AKT kinase activity in
human breast cancer lines. Subconfluent proliferating culture of breast
cancer lines (MCF-7 and MDA-MB-468), immortalised breast epithelial line
(MCF10A), and normal primary HMEC were harvested and lysed. Proteins
(100mg) derived from such lysate were subjected to Western blot analysis
using phosphor-specific primary antibodies to detect various phosphory-
lated proteins (A). In addition, 500mg of protein from the same lysates
were immunoprecipitated with anti-AKT antibody and the resulting
immune complexes were further subjected to AKT kinase activity assays
using GSK-3a/b as a substrate. The presence of phosphorylated GSK-3a/b
(Ser21/Ser9) indicates positive AKT kinase activity in cells (B).
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skey protein kinases that phosphorylates Stat3 at S727 (Calo et al,
2003; Clevenger, 2004; Yonezawa et al, 2004). We thereby
examined Stat3 phosphorylation on S727 using Western blotting.
As shown in Figure 3A, elevated phosphorylation of Stat3(S727)
was prominent in MDA-MB-468, modest in MCF-7, as compared
to MCF10A and HMEC. It is in close agreement with data from
Kinexus phosphorylated protein screening assays demonstrating
phosphorylation of Stat3 at S727 was only elevated in MDA-MB-
468, but not in MCF-7. All together, these results hence suggest
phosphorylation of Stat3(S727) may be prevalent to higher degree
of breast cancer lines such as MDA-MB-468.
Additional studies on Stat3(S727) in primary breast tumours
using Stat3(Y705) as a control were carried out by applying IHC
staining on TMA slides. As shown in Table 2, we found 40 (44.9%)
and 23 (25.8%) out of 89 breast cancer tissues retained elevated
phosphorylation on residues S727 and on Y705, respectively.
Nevertheless, phosphorylated Stat3 on either residue significantly
associated with invasive breast tumours (Po0.05, Table 2) and
predominantly localised in the nuclei (Figure 1).
Phosphorylated EGFR(Y1068) was exclusively in the
nucleus of breast tumours
Although EGFR was suggested to be one of upstream regulators of
PDK-1/AKT and Stat3 pathways (Engelman et al, 2005; Ivanov and
Hei, 2005; Phillips et al, 2005), the role of EGFR activation plays
in relation to PDK-1/AKT/mTOR/p70S6K/S6 cascade in breast
cancers has not been firmly established. In this study, we have
shown that moderate to high levels of EGFR phosphorylation
(Y1086) were observed in 67 out of 89 (75.3%) primary breast
tumours and was associated with invasive breast tumours
(Po0.05) (Table 1). Interestingly, the phosphorylated EGFR was
predominantly in the nuclei (Figure 1), which was in strong
agreement as other studies, suggested that the nuclear EGFR
positively associated with poor survival outcomes in patients with
breast cancer (Lo et al, 2005). Moreover, elevated phosphorylation
on EGFR(Y1068) was dramatically increased in MDA-MB-468, but
not in MCF-7, as evidenced by the results from Kinexus screening
assays (Table 1) and from Western blots (Figure 3A). It suggest
EGFR(Y1068) might serve as a promising molecular diagnostic
marker to differentiate higher stage from lower degree of breast
cancer and noncancerous mammary epithelial cells.
Concomitant phosphorylation of PDK-1 with other
downstream kinases
As PDK-1 phosphorylation was implicated as an apex pivotal
intracellular signalling molecules, we then investigated if phos-
phorylated PDK-1 positively correlates the phosphorylation of
putative downstream targets in breast caricinomas. Thus, the
Bivariate Pearson w
2 tests were performed to statistically relate the
phosphorylation of PDK-1 to other kinases that were studied in
this report. As shown in Table 2, phosphorylation of EGFR and the
remaining kinases were all correlated with PDK-1 phosphorylation
(Po0.05), suggesting that EGFR might be one of the upstream
regulators whereas other remaining kinases are downstream of
PDK-1 pathway in breast carcinoma. However, the correlation in
the transcription factor Stat3 phosphorylation is somewhat
different. Although Stat3 (S727) remains correlate well with
kinases in this cascade including EGFR, PDK-1, AKT, mTOR,
p70S6K and S6 (Po0.05 in Table 1), phosphorylated Stat3 (Y705)
did not correlate with PDK-1 phosphorylation in this study
(P40.05; Table 2), despite it is associated with invasive breast
carcinoma (Po0.05; Table 2). It hence suggests that Stat3
phosphorylation (Y705) was likely accomplished by different
kinase(s) that were excluded from PDK-1/mTOR/p70S6K/S6K
pathway and further support the notion indicating phosphoryla-
tion on these two residues was mediated by independent signalling
events (Jain et al, 1999; Yokogami et al, 2000; Garcia et al, 2001;
Lim and Cao, 2001; Yonezawa et al, 2004).
Frequent elevation of PDK-1 phosphorylation at residue
S241 in high stages of breast cancer
Out of total 89 breast tumours, 83 were pathologically categorised
into four stages as shown in Table 3. Although the correlation
between kinase phosphorylation and the stages of breast tumours
was attempted, the statistically significant correlation was un-
achievable to be established due to low numbers at stages 1 and 3
(N¼3 and 7, respectively). However, remarkably high frequency
of moderate to high level (scores 2 and 3 in IHC staining) of
phosphorylation on PDK-1(S241), AKT(T308) and p70S6K(T389)
was found at high stages of breast cancer (stages 3 and 4). Up to
86% of metastasised breast tumour (stage 4) retained elevated
phosphorylation on both PDK-1(S241) and AKT(308) whereas
100% of stage 3 and 76% of stage 4 revealed moderate to high level
of phosphorylation on p70S6K(T389) (Table 3).
DISCUSSION
To examine the molecular pathogenesis involving oncogene
activation in breast carcinoma, we compared phosphorylation
levels of 10 protein kinases as well Stat3 and c-Jun between normal
primary HMEC and breast cancer cell lines and have identified the
activation of PDK-1/AKT may play important roles in breast
tumorigenesis. The diverse phosphorylation profiles in breast
cancer lines (Table 1) suggested these molecules may attribute
somewhat differently in breast tumorigenesis. Elevated phosphory-
lation of PDK-1, mTOR and increased AKT kinase activity in both
MDA-MB-468 and MCF-7 breast cancer cell lines (Table 1, Figure
3A and B) indicated that they may play important roles in breast
carcinogenesis. However, these results might be misleading
because additional genetic alteration(s) or kinase activation might
be generated from the long-term in vitro culture of these two
breast cancer cell lines. We hence performed similar studies on
TMA slides fixed with primary breast tumours using phosphor-
specific antibodies in IHC staining assays. In our both studies,
however, similar findings were obtained regardless the source of
breast cancer cells (Tables 1 and 2) and thus confirmed the
importance of PDK-1/AKT/mTOR/p70S6K activation in breast
cancer.
Noticeably, all kinases that we examined in this study gave rise
to enhanced phosphorylation in one or both breast cancer lines,
with an exception of c-Jun (Table 1). In fact, the roles of c-Jun in
human cancer remained controversial. Conflict reports have
indicated it may function as a proapoptotic (Cuadrado et al,
2004; Qi et al, 2004) or antiapoptotic mediators (Johnsto et al,
1999; Huang et al, 2004) determined upon cellular context.
However, our finding of decreased c-Jun phosphorylation in both
breast cancer cell lines hence suggested that c-Jun was unlikely an
antiapoptotic or proto-oncogene in those two breast cancer cell
lines.
The pivotal roles involving activation of PDK-1 were investi-
gated in this study. Although PDK-1 is an upstream kinase of AKT
and transfection of PDK-1 cDNA can induce transformation of
cells (Zeng et al, 2002), the activation of PDK-1 has not been
demonstrated in primary breast carcinoma, yet. First, we showed
that the phosphorylation PDK-1 at S241 was elevated in both
human breast cancer cell lines compared to normal or immorta-
lised mammary epithelial cell HMEC (Table 1, Figure 3A). Then
similar findings were obtained as elevated phosphorylation of
PDK-1 was found in 81% of invasive primary breast tumours
(Table 2). This was the first report illustrating PDK-1 phosphory-
lation was frequently elevated and was significantly associated
with the invasiveness of breast carcinoma (Po0.05, Table 2).
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metastasised breast tumours retained moderate to high level
of phosphorylation on PDK-1(S241) (Table 3), indicating the
aggressive metastasis of breast cancers somehow rely on the
phosphorylation and subsequent activation on PDK-1.
Concomitant phosphorylation of putative downstream targets of
PDK-1 was evidenced by applying IHC staining on invasive breast
tumours using phospho-specific antibodies (Table 2, Figures 1 and
2). One of the most extensively studied targets of PDK-1 was AKT,
which can be activated by phosphorylation on two residues (T308
and S473) for full oncogenic activity (Bellacosa et al, 1998).
Although phosphorylation of AKT at T308 was mediated by PDK-1
(Alessi et al, 1997; Wick et al, 2000a), phosphorylation of AKT at
S473 may be involved by other kinases including putative PDK-2
(Hresko et al, 2003), integrin-linked kinase (ILK) (Persad et al,
2001), protein kinase C-a (Partovian and Simons, 2004), DNA-
dependent protein kinase C (Feng et al, 2004) or Rictor-mTOR
complex (Sarbassov et al, 2005). Interestingly, we have shown the
phosphorylation of AKT on T308 resembled well with that of PDK-
1 in breast cancer (Tables 2 and 3, Figures 1 and 2), which agreed
with other results demonstrating residue T308 of AKT was directly
phosphorylated by PDK-1 (Alessi et al, 1997; Wick et al, 2000b;
Williams et al, 2000). This is the first report that illustrated
significant correlation between phosphorylation of PDK-1 and
AKT (Thr308) and supported that PDK-1 is an AKT (T308) kinase
in invasive breast tumours in vivo.
On the other hand, phosphorylation of AKT on S473 is less
frequent (34.8%) and weaker in intensity in the invasive breast
carcinomas (Tables 2 and 3, Figure 2) than AKT on T308 (80.9%)
or PDK-1 (80.9%), suggesting that phosphorylation of former
residues was less frequently detected than later ones in the invasive
breast tumours. Interestingly, all (100%) of breast cancers that
expressed moderate to high level of AKT(S473) concomitantly
retained elevated phosphorylation on AKT(T308), indicating an in
vivo clinical correlation between them. Perhaps, phosphorylation
of AKT(T308) is a upstream prerequisite for the downstream
phosphorylation on AKT(S473). This hypothesis is currently under
further investigation in our laboratory.
It was reported that nuclear localisation of activated PDK-1 was
to sequestrate downstream targets. As mutations that abolished
cytoplasmic trafficking diminished anchorage-dependent growth
and failed to protect against UV-induced apoptosis, indicating
cytoplasmic localisation of PDK-1 plays pivotal roles in signalling
(Lim et al, 2003). In our study, phosphorylated PDK-1 appears to
be predominantly cytoplasmic localised as shown in Figure 1, which
is the same subpopulation that activate downstream signalling
cascade (Lim et al, 2003; Scheid et al, 2005). In addition, we and
others have reported that phosphorylated PDK-1, AKT, mTOR,
and S6K accumulate predominately in the cytoplasm, whereas
EGFR, p70S6K, and Stat3 are in the nucleus. It hence suggested
translocation mechanisms were involved in transmitting signals
between cytoplasmic and nuclear compartments. Although the
molecular mechanisms pertaining nuclear localisation of EGFR have
not been identified yet, Spinophilin was reported to be one of the
scaffolding molecule that binds to p70S6K (Buchsbaum et al, 2003).
The finding of concomitant phosphorylation of kinases down-
stream from PDK-1 was manifested in this study. The phosphory-
lation of the putative downstream kinases was positively
associated with PDK-1 phosphorylation and together correlated
with the invasive breast tumours (Po0.05, Table 2). Although we
have attempted to correlate the stages and distal metastasis of
breast tumours to the phosphorylation of kinases in the PDK-1/
AKT pathways, we were unable to obtain statistically significant
data due to insufficient numbers of breast tumours in various
stages (Table 3). However, the elevated phosphorylation on mTOR
and Stat3 was noticeably differed from that on PDK-1 in various
stages of breast cancer, indicating these molecules are not in a
single linear signalling cascade regulated by PDK-1. Instead,
additional regulators (or pathways) are involved and multiple
networking signalling pathways may interplay, which all together
in part lead to breast tumours. For example, recent studies have
suggested that TSCI and II function together to negatively regulate
the insulin signalling pathways, including mTOR (Gao and Pan,
2001). Similarly, additional regulatory pathways other than PDK-1
are likely controlling Stat3 activation as demonstrated by
phosphorylation on Y705 was only moderately associated with
S727 and was statistically unrelated to PDK-1 phosphorylation
(P40.05 in Table 2). Nevertheless, we are currently investigating
the molecular aetiologic mechanisms of kinase phosphorylation/
activation, which perhaps involve genetic alterations leading to
constitutive activation of the upstream apex receptor kinases.
In general, in vitro findings are preliminary in nature and
require further validation in vivo with clinical studies or with
laboratory xenograft animal models. However, our observation as
frequent deregulation in the PDK-1/AKT/mTOR/p70S6K signalling
pathway and its prognostic role in breast cancers implicated the
notion of using inhibitors to impair this pathway and to provide
additional strategy to treat breast cancer. Moreover, the detection
of phosphorylated PDK-1, AKT, or mTOR through the simplicity
and reproducibility of IHC staining might provide the treatment
regimen that simultaneously inhibit multiple kinases within the
same signalling pathway, ensure the blockage of the pathway,
which ultimately reverse the malignant phenotypes. Among the
options of drugs, inhibitors that abrogate the most upstream apex
signalling pathways, such as PDK-1, should provide better clinical
treatment efficacy as they disable far more downstream signalling
molecules.
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